MITRAL VALVE PROCEDURES UAB ’ s expert team of physicians works to determine the appropriate mode of treatment , whether that ’ s open surgery , robotic-assisted procedures , or an interventional procedure ( MitraClip ).
The commercially available MitraClip is indicated for a transcatheter approach to mitral valve repair using the edge-toedge technique for patients with degenerative , functional , or mixed mitral regurgitation . MitraClip in-house mortality over the one-year period from July 2020 to July 2021 has been zero , which highlights the remarkable “ heart team ” approach
MITRAL VALVE REPAIR 2018-2020
MITRACLIP VOLUMES AND MORTALITY JULY 2020-JUNE 2021
STRUCTURAL HEART & VALVE DISEASE for our transcatheter valve program .
TRANSCATHETER AORTIC VALVE REPLACEMENT The transcatheter aortic valve replacement ( TAVR ) procedure is used to treat patients with aortic stenosis who are considered to be inoperable or as an alternative for patients whose risk is high , intermediate , or low . UAB ’ s transcatheter valve program began in 2012 , and it has performed over 2,000 TAVR procedures to date . A multidisciplinary team of cardiothoracic surgeons , interventional cardiologists , cardiac imaging specialists , cardiac anesthesiologists , advanced practitioners , nurses , psychologists , and members of the quality team collaborate to provide comprehensive , high-quality , and patient-centered care .
We are a referral center for complex TAVR procedures and receive a large number of referrals from other TAVR centers , given our expertise . Offering alternative access further exemplifies the overall strength of our team in caring for this highrisk , complex patient population .
Alternative access for TAVR is offered for patients with severe peripheral vascular disease and other anatomic variations that preclude a standard transfemoral approach .
At the UAB Cardiovascular Institute , we are proud of our outcomes . The TAVR RISK Standardized In-Hospital Mortality Odds Ratio for R3Y ( rolling three years ) currently is performing well above the 90th percentile among TAVR Registry participants . Additionally , our CY 2020 in-hospital actual mortality was 0.2 %.
TAVR RISK STANDARDIZED IN-HOSPITAL MORTALITY ODDS RATIO ( R3Y )
TAVR ACCESS 2018-2020
Source : NCDR STS / ACC TVT Registry Executive Summary Report Q1 2018 – Q4 2020 R3Y uabmedicine . org 5